GÜVENİR ÇELİK, E. And EROĞLU, O. 2024. Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1. Molecular Biology Reports , vol.51, no.1 .

GÜVENİR ÇELİK, E., & EROĞLU, O., (2024). Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1. Molecular Biology Reports , vol.51, no.1.

GÜVENİR ÇELİK, ESİN, And ONUR EROĞLU. "Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1," Molecular Biology Reports , vol.51, no.1, 2024

GÜVENİR ÇELİK, ESİN G. And EROĞLU, ONUR. "Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1." Molecular Biology Reports , vol.51, no.1, 2024

GÜVENİR ÇELİK, E. And EROĞLU, O. (2024) . "Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1." Molecular Biology Reports , vol.51, no.1.

@article{article, author={ESİN GÜVENİR ÇELİK And author={ONUR EROĞLU}, title={Ruxolitinib-loaded poly-ɛ-caprolactone (PCL) nanoparticles inhibit JAK2/STAT5 signaling in BT474 breast cancer cells by downregulating Bcl-2 and Mcl-1}, journal={Molecular Biology Reports}, year=2024}